Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.58 |
| ▸ | HRH1 | P35367 | 2/20 | 0.58 |
| ▸ | L3MBTL3 | Q96JM7 | 7/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | MBTD1 | Q05BQ5 | 4/20 | 0.54 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.54 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4672614 | 0.92 | HRH3 (0.64) | KMT2AMEN1HRH3HRH1L3MBTL1 | |
| SCHEMBL4670476 | 0.91 | HRH3 (0.54) | KMT2AMEN1HRH3HRH1L3MBTL3 | |
| SCHEMBL4670371 | 0.90 | HRH3 (0.63) | KMT2AMEN1HRH3HRH1KCNH2 | |
| SCHEMBL4670291 | 0.84 | ALDH1A1 (0.68) | KMT2AMEN1HRH3HRH1ALDH1A1 | |
| SCHEMBL4672610 | 0.83 | HRH3 (0.69) | KMT2AMEN1HRH3ALDH1A1HTT | |
| SCHEMBL4619912 | 0.81 | HRH3 (0.66) | KMT2AMEN1HRH3ALDH1A1HTT | |
| SCHEMBL4670549 | 0.81 | HRH3 (0.67) | HRH3 | |
| SCHEMBL3076252 | 0.80 | HRH3 (0.86) | KMT2AMEN1HRH3HRH1L3MBTL3 | |
| SCHEMBL4233234 | 0.79 | HRH3 (0.63) | KMT2AMEN1HRH3HRH1KCNH2 | |
| SCHEMBL14006759 | 0.79 | HRH3 (0.89) | HRH3HRH1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1610786-B9 | 4-(4-(HETEROCYCLYLALKOXY PHENYL)-1-(HETEROCYCLYL-CARBONYL)PIPERIDINE DERIVATIVES AND RELATED COMPOUNDS AS HISTAMINE H3 ANTAGONISTS FOR THE TREATMENT OF NEUROLOGICAL DISEASES SUCH AS ALZHEIMER'S | GLAXO GROUP LTD (GB) | 2008-02-27 | — | — | EP | claimed |
| EP-1610786-B1 | 4-(4-(HETEROCYCLYLALKOXY PHENYL)-1-(HETEROCYCLYL-CARBONYL)PIPERIDINE DERIVATIVES AND RELATED COMPOUNDS AS HISTAMINE H3 ANTAGONISTS FOR THE TREATMENT OF NEUROLOGICAL DISEASES SUCH AS ALZHEIMER'S | GLAXO GROUP LTD (GB) | 2007-06-20 | — | — | EP | claimed |
| US-20060205774-A1 | 4-(4-(Heterocyclylakoxy) phenyl-1-(heterocyclyl-carbonyl) piperidine derivavites and related compounds as histamine h3 antagonists for the treatment of neurological diseases such as alzheimer's | GLAXO GROUP LIMITED (GB) | 2006-09-14 | — | — | US | claimed |
| EP-1610786-A1 | 4-(4-(HETEROCYCLYLALKOXY PHENYL)-1-(HETEROCYCLYL-CARBONYL)PIPERIDINE DERIVATIVES AND RELATED COMPOUNDS AS HISTAMINE H3 ANTAGONISTS FOR THE TREATMENT OF NEUROLOGICAL DISEASES SUCH AS ALZHEIMER'S | GLAXO GROUP LIMITED (GB) | 2006-01-04 | — | — | EP | claimed |
| WO-2004089373-A1 | 4- (4-(HETEROCYCLYLALKOXY}PHENYL)-1-(HETEROCYCLYL-CARBONYL)PIPERIDINE DERIVATIVES AND RELATED COMPOUNDS AS HISTAMINE H3 ANTAGONISTS FOR THE TREATMENT OF NEUROLOGICAL DISEASES SUCH AS ALZHEIMER’S | GLAXO GROUP LIMITED (GB) | 2004-10-21 | — | — | WO | claimed |
| EP-1610786-B9 | 4-(4-(HETEROCYCLYLALKOXY PHENYL)-1-(HETEROCYCLYL-CARBONYL)PIPERIDINE DERIVATIVES AND RELATED COMPOUNDS AS HISTAMINE H3 ANTAGONISTS FOR THE TREATMENT OF NEUROLOGICAL DISEASES SUCH AS ALZHEIMER'S | GLAXO GROUP LTD (GB) | 2008-02-27 | — | — | EP | disclosed |
| EP-1610786-B1 | 4-(4-(HETEROCYCLYLALKOXY PHENYL)-1-(HETEROCYCLYL-CARBONYL)PIPERIDINE DERIVATIVES AND RELATED COMPOUNDS AS HISTAMINE H3 ANTAGONISTS FOR THE TREATMENT OF NEUROLOGICAL DISEASES SUCH AS ALZHEIMER'S | GLAXO GROUP LTD (GB) | 2007-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205774-A1 | 4-(4-(Heterocyclylakoxy) phenyl-1-(heterocyclyl-carbonyl) piperidine derivavites and related compounds as histamine h3 antagonists for the treatment of neurological diseases such as alzheimer's | HRH3, HRH4, HRH1 | KMT2A 147/4885MEN1 2905/4885HRH3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.